PATENT CLAIM ANALYSIS

Application Number: 15936192
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "021900"]

Abstract:
The present invention relates to methods of preventing or treating skin necroptosis diseases, including administering to subjects receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blockers or dabrafenib, and method of diagnosing of skin necroptosis diseases, including detecting phosphorylated MLKL. The RIP3-MLKL pathway blockers according to the present invention directly suppress RIP3 overexpressing in skin necroptosis diseases, or inhibit phosphorylation and translocation to plasma membranes of MLKL, subsequently induced therefrom, thereby effectively preventing skin cell death via necroptosis. Thus, the present invention can prevent or treat a variety of skin diseases caused by necroptosis.

Claim (Index 20):
The method of  claim 13 , wherein the skin necroptosis disease is lichen planus.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 90.0
- Lexical Diversity: 1.70769
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15017470', '15116591', '15768388', '14214360', '15093480']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7183464075478915
- 35 USC 102 Novelty (BERT): 0.6417440911495791
- Combined Prediction Score: 0.7106861759080602
- Mean Citation Score: 319.47696
- Max Citation Score: 701.2049
- Similarity Product: 522.8817661275923

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test